Kura Oncology, Inc.

Contributing Author

Recent Articles by Kura Oncology, Inc.

Jun-12	Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress KURA GlobeNewswire
Jun-06	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
Jun-02	Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting KURA GlobeNewswire
Jun-01	Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML KURA GlobeNewswire
May-22	Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting KURA GlobeNewswire
May-20	Kura Oncology to Participate in Three Upcoming Investor Conferences KURA GlobeNewswire
May-14	Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress KURA GlobeNewswire
May-06	Kura Oncology to Participate in Bank of America Securities Healthcare Conference KURA GlobeNewswire
May-02	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) KURA GlobeNewswire
May-01	Kura Oncology Reports First Quarter 2025 Financial Results KURA GlobeNewswire